Leading the Way in Life Science Technologies

GEN Exclusives

More »

Columns

More »

For full access to this article login to GEN Select now.

Feb 1, 2014 (Vol. 34, No. 3)

miRNA Therapeutics Heading to the Clinic

Despite Great Challenges, a Number of Companies Are Committed to Development Programs

  • Currently, there are two segments of the microRNA research marketplace that are translating toward the clinic: miR signatures as biomarkers with utility in diagnostics ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »